Inozyme Pharma, Inc. (INZY) Misses Q1 EPS by 3c

Inozyme Pharma, Inc. (NASDAQ: INZY) reported Q1 EPS of ($0.38), $0.03 worse than the analyst estimate of ($0.35).

For earnings history and earnings-related data on Inozyme Pharma, Inc. (INZY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15